Patricia Inácio, PhD,  science writer—

INOmax EVOLV DS, a device to deliver nitric oxide gas by inhalation to newborns with pulmonary hypertension (PH), is expected to be available in hospitals in the U.S. in the first half of 2024. The U.S. Food and Drug Administration (FDA) has cleared the next-generation device, developed by…

The noninvasive CPET test — known in full as cardiopulmonary exercise testing, which determines how the heart responds to exercise — may help to identify pulmonary arterial hypertension (PAH) patients at higher risk of clinical worsening, according to a new study in the U.S. The presence of heart rhythm…

A professor of pediatric cardiology at Stanford University School of Medicine will receive the American Heart Association 2023 Research Achievement Award, in recognition of her work in pulmonary arterial hypertension (PAH). Marlene Rabinovitch, MD, will receive the award Nov. 12 during the Presidential Session of the Association’s Scientific…

Higher pressure in the heart’s top left chamber — a parameter called pulmonary arterial wedge pressure (PAWP) — is a likely predictor of poorer outcomes in people with pulmonary hypertension (PH) due to left heart disease, a study reports. PAWP was measured using the inhaled nitric oxide (iNO) vasoreactivity…

Triple combination therapy — used to target multiple pathways — improves lung and heart function in pulmonary arterial hypertension (PAH) patients, according to real-world data from a racially diverse group. The combo therapy resulted in a significant easing of disease severity, with no patient classified as high risk. Being…

An echocardiogram during pregnancy, particularly at the third trimester, may help in predicting a risk of persistent pulmonary hypertension of the newborn (PPHN), a study from China suggests. Echocardiograms, which measure heart function using sound waves, are noninvasive and widely used in diagnosing pulmonary hypertension (PH) in people,…

Inhaled nitric oxide (iNO) therapy reduces the risk of death in preterm infants with severe hypoxemic respiratory failure (HRF) — low oxygen in the blood — and suspected or confirmed pulmonary hypertension (PH), a study shows. “The findings provide evidence supporting the prognostic value of oxygenation response and support…

Liquidia is seeking to extend the tentative approval of Yutrepia, an inhaled dry powder formulation of treprostinil for pulmonary arterial hypertension (PAH), to include pulmonary hypertension associated with interstitial lung disease (PH-ILD). PH-ILD occurs when blood pressure in the lungs is high due to a disease that causes lung…

Keros Therapeutics has announced that it will launch a Phase 2 trial to assess the effectiveness of KER-012 as an add-on treatment for patients with pulmonary arterial hypertension (PAH). This follows the recent clearance by the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND)…

Pregnant women with mild pulmonary hypertension (PH) show a significantly lower risk of maternal and fetal complications than those with moderate-to-severe PH, according to a study from China. “For patients with mild pulmonary hypertension and good cardiac function, continued pregnancy or even delivery should be considered under multidisciplinary monitoring,”…

Long COVID syndrome can be common among people with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), affecting more than 60% of patients infected with the SARS-CoV-2 virus in a study from Poland. Despite the persistence of COVID-19 symptoms, no change was evident in the patients’ risk of…

People with pulmonary arterial hypertension (PAH) and their caregivers place different value on the parameters used to evaluate clinical worsening in trials, according to the findings of a survey in Canada. Patients attributed significant importance to lacking clinical improvement, needing long-term oxygen therapy, and any decrease in health-related quality…